Table 4 SARS-CoV-2 pseudotyped variants features and CD147 antibody inhibition rate
Pseudotyped virus name | Country of origin | Mutations (AA) | Meplazumab inhibition rate (60 μg/ml) | Source |
|---|---|---|---|---|
SARS-CoV-2 | China | 58.7% | National Institutes for Food and Drug Control, China | |
Alpha | United Kingdom | HV69-70 Del, Y145 Del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H | 68.2% | |
Beta | South Africa | D80A, D215G, LAL242–244 Del, E484K, K417N, N501Y, D614G, A701V | 69.4% | |
Eta | Denmark, America | Q52R, A67V, H69del, V70del, Y144del, E484K, D614G, Q677H, F888L | 75.3% | |
Lota (S477N) | America | L5F, T95I, D253G, S477N, D614G, Q957R | 76.0% | |
Lota (E484K) | America | L5F, T95I, D253G, E484K, D614G, A701V | 65.2% | |
Gamma | Brazil | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F | 50.3% | |
Zeta | Brazil | E484K, D614G, V1176F | 46.0% | |
Kappa | India | T951, G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H | 8.37% | |
Delta | India | T19R, G142D, F157del, L452R, T478K, D614G, P681R, D950N | 47.3% |
